trestolone

Trestolone (7α-methyl-19-nortestosterone; MENT) is a synthetic androgen and anabolic steroid developed primarily by the Population Council as a potential hormonal male contraceptive and for androgen replacement therapy[1][2][8]. It is a derivative of nandrolone with a methyl group at the C7α position that enhances its androgenic properties[6]. Trestolone acts as a potent inhibitor of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to suppression of endogenous testosterone production and impaired spermatogenesis[2][5][8]. This results in reversible azoospermia or oligospermia in males. Trestolone binds to the androgen receptor with high affinity, stimulating protein synthesis and muscle growth while also undergoing aromatization to estrogen like testosterone[6][5]. Although it demonstrated strong anabolic effects—reportedly ten times that of testosterone—it has not been approved or marketed for medical use due to safety concerns. Clinical development reached phase II trials for male contraception and treatment of low testosterone but was discontinued[5][7].

Other names

trestolone acetatetrestolone enanthatemethylbolonemetribolone